InsideMS; Summer 2002; Vol. 20, Issue 3
Mike Dugan, General, USAF, Ret., President and CEO
Expensive—characterized by high price or cost that sometimes exceeds… a prospective buyer’s financial resources.
Webster’s Third New International Dictionary
The FDA’s approval of Rebif brings yet another choice for people with MS in an expanding menu of treatment options. But for most of us the word that comes to mind is not options, but expensive.
We can argue that the expense is an illusion. The corporations that sell these medications offer people outstanding—and expensive—support: telephone hotlines, training in injection technique, publications, educational conferences, savvy counseling about getting the most from insurance or pharmacy assistance programs, and limited financial assistance to the underinsured and overwhelmed.
Even so, we have an expensive truth: the high cost of these drugs is part of a pattern that terrifies taxpayers, insurance companies, and the business community. We are in a national health-care financing crisis as all the costs of health care rise.
Remedies all too often target prescription drugs. Some insurance plans have no drug coverage, some plans are reducing coverage, and some are shifting more costs to patients. The players include private insurance plans and public plans governed by the federal government or the states. To get fair treatment for people with expensive illnesses we need all the influence we can muster. I invite everyone to join us in advocating for:
© 2002 The National Multiple Sclerosis Society